Business
Interim Results and Investor Presentation
EMV Capital PLC announced its interim results for the six months ended 30 June 2025. Group revenue slightly decreased to £1.1 million from £1.2 million in H1 2024, with £1.0 million coming from EMV Capital core revenue. Group losses decreased to £1.5 million, compared to £1.8 million in H1 2024. Total assets increased to £19.7 million from £19.5 million at FY 2024, while net assets decreased slightly to £13.6 million. Adjusted net assets decreased to £29.3 million. Cash on the balance sheet was £0.5 million, with £1.0 million in readily realisable quoted securities. Total Assets Under Management stood at £104.7 million. EMV Capital Partners syndicated £5.0 million in new investments. Post balance sheet, Martlet Capital received exit proceeds of c.£320k and EMV Capital acquired IP and clinical assets from Destiny Pharma for up to £2.475 million. Disclaimer*
About this update from Emv Capital Plc
[{"type":"text","content":"\n\nStrictly embargoed for: 07.00 a.m. on 30 September 2025\n \nEMV Capital PLC\n(EMV Capital or EMVC or the Company or the Group)\nInterim Results for the six months ended 30 June 2025\nand Investor Presentation\nEMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, today announces its interim results for the six months ended 30 June 2025.\nAnalyst and Investor Presentation\nA live results meeting will be held online on the Investor Meet Company platform at 10.00 BST today (30 September 2025). This presentation is open to all interested parties. Anyone can sign up for free to the Investor Meet Company platform and join the live presentation using the following link:\nhttps://www.investormeetcompany.com/emv-capital-plc/register-investor\nThose who already follow the Company on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted at any time during the live presentation.\nFinancial and Operational Highlights\nGroup Performance\n\nThe Group's performance includes the operational 'core' of EMV Capital plc, EMV Capital Partners and other EMV Capital operating companies, alongside subsidiary portfolio companies where the Group holds over a 50% shareholding.\nGroup revenue decreased slightly to £1.1 million (H1 2024: £1.2 million), comprising:\n\n£1.0 million from EMV Capital core revenue (H1 2024: £1.0 million), which covered approximately 79% of the core Group's costs for the period whilst also providing infrastructure and services to the Group and its portfolio companies; and\n£0.1 million from ProAxsis (H1 2024: £0.2 million), reflecting production delays of its work-in-progress pipeline.\n\n\nGroup losses for the period decreased to £1.5 million (H1 2024: £1.8 million), comprising:\n\n£0.3 million attributed to the core EMV Capital operations (H1 2024: £0.6 million); and\n£1.2 million attributed to the subsidiary portfolio companies, ProAxsis and Glycotest (H1 2024: £1.2 million).\n\n\nTotal Assets increased to £19.7 million (FY 2024: £19.5 million), whilst net assets decreased slightly to £13.6 million (FY 2024: £14.1 million). After adjustment to account for the full fair value of the Group's subsidiary portfolio companies adjusted net assets decreased to £29.3 million (FY 2024: £29.9 million).\nThere were no divestments during the period (H1 2024: £Nil)....